Brown, J., Black, R., Phan, H., Chapis, K., Pazienza, S., Re, S., Tyekucheva, S., Ahn, I., Davids, M. S., Veen, L. V. D., Lahn, M., Armand, P. (2025). Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). Blood. https://doi.org/10.1182/blood-2025-3913